Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has been assigned a $10.00 target price by investment analysts at B. Riley in a report released on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. B. Riley’s target price indicates a potential upside of 138.10% from the company’s previous close. B. Riley also issued estimates for Adamis Pharmaceuticals Corporation’s Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.78) EPS, Q1 2018 earnings at ($0.14) EPS, Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.17) EPS, Q4 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.60) EPS, FY2019 earnings at ($0.56) EPS, FY2020 earnings at ($0.50) EPS and FY2021 earnings at ($0.37) EPS.

A number of other brokerages have also recently commented on ADMP. Raymond James Financial, Inc. assumed coverage on Adamis Pharmaceuticals Corporation in a research note on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price target for the company. ValuEngine cut Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Finally, Maxim Group reaffirmed a “buy” rating and issued a $13.00 price target on shares of Adamis Pharmaceuticals Corporation in a research note on Monday, August 21st.

Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) traded up $0.05 during mid-day trading on Wednesday, hitting $4.20. The stock had a trading volume of 750,309 shares, compared to its average volume of 618,967. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79. Adamis Pharmaceuticals Corporation has a one year low of $2.55 and a one year high of $6.45.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/19/b-riley-analysts-give-adamis-pharmaceuticals-corporation-admp-a-10-00-price-target.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Allied Advisory Services Inc. bought a new stake in Adamis Pharmaceuticals Corporation during the 2nd quarter worth approximately $114,000. Bank of New York Mellon Corp increased its stake in Adamis Pharmaceuticals Corporation by 131.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock worth $143,000 after purchasing an additional 15,577 shares in the last quarter. Stonebridge Capital Advisors LLC increased its stake in Adamis Pharmaceuticals Corporation by 22.2% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock worth $143,000 after purchasing an additional 5,000 shares in the last quarter. Wells Fargo & Company MN bought a new stake in Adamis Pharmaceuticals Corporation during the 2nd quarter worth approximately $169,000. Finally, IFP Advisors Inc increased its stake in Adamis Pharmaceuticals Corporation by 2,245.6% during the 2nd quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock worth $179,000 after purchasing an additional 32,965 shares in the last quarter. 9.93% of the stock is owned by institutional investors and hedge funds.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.